Lymphoma: all 5,624 studies

Page 51 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma PatientsTerminatedNCT00120198Phase 2
• Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaCompletedNCT00119730Phase 2
• Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous DiseaseCompletedNCT00118326Phase 1/2
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaCompletedNCT00117975Phase 2
• Treatment for Subjects With Non-Hodgkin's LymphomaCompletedNCT00117897Phase 2
• A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's LymphomaCompletedNCT00117455Phase 2
• Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular LymphomaCompletedNCT00115700Phase 3
• Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's LymphomaCompletedNCT00115193Phase 2
• Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00112931Phase 3
• Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid TumorsTerminatedNCT00112619Phase 1
• Healthy Exercise for Lymphoma Patients (HELP)Status unknownNCT00111865Phase 3
• Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00110071Phase 1
• Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaWithdrawnNCT00110006Not applicable
• Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
• Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
• Temozolomide and Topotecan in Treating Patients With Primary CNS LymphomaWithdrawnNCT00109798Not applicable
• Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LeukemiaStatus unknownNCT00109356Phase 1/2
• Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaTerminatedNCT00105313Phase 1
• Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00104975Phase 1
• Fenretinide in Treating Patients With Refractory or Relapsed Hematologic CancerCompletedNCT00104923Phase 1
• Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's LymphomaTerminatedNCT00104819Phase 2
• A Safety Study of SGN-40 in Patients With Non-Hodgkin's LymphomaCompletedNCT00103779Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
• Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis FungoidesCompletedNCT00103246Phase 1
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
• Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
• Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00100737Phase 2
• Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00100711Phase 2
• Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid TumorsTerminatedNCT00100347Phase 1
• Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell LymphomaCompletedNCT00099255Phase 2
• MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
• Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00098566
• Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaCompletedNCT00098332Phase 1
• An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)CompletedNCT00097929Phase 2
• An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00097565
• Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)CompletedNCT00094848Phase 2
• Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00093769Phase 2
• Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive LymphomaTerminatedNCT00093704Phase 1
• Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced CancerWithdrawnNCT00093678Not applicable
• Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular LymphomaWithdrawnNCT00092274Phase 1/2
• Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular LymphomaStatus unknownNCT00091676Phase 3
• Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)CompletedNCT00091559Phase 2
• Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's LymphomaCompletedNCT00091091
• Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00090909Phase 2
• Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaStatus unknownNCT00090727Phase 1
• Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00090090Phase 2
• Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00090038Phase 4
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00089154Phase 2
• Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaTerminatedNCT00089115Phase 3
• Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
• 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or LymphomaCompletedNCT00088868Phase 1
• Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
• Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell TransplantationTerminatedNCT00087009Phase 1
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's LymphomaCompletedNCT00086801Phase 2
• Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's LymphomaCompletedNCT00086034Phase 2
• Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or LymphomasCompletedNCT00085904Phase 1
• VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
• Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00085449Phase 1/2
• LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaCompletedNCT00085150Phase 1
• Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant DiseasesStatus unknownNCT00084695Phase 2
• Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00083213Phase 1
• Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2
• Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS LymphomaCompletedNCT00082836Not applicable
• Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00082823Phase 1
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• Study of the Emotional Needs of Caregivers of Stem Cell Transplantation PatientsCompletedNCT00082654Not applicable
• Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's LymphomaCompletedNCT00082303Phase 1/2
• LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)TerminatedNCT00082225Phase 1
• A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaCompletedNCT00081809Phase 2
• Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) PatientsStatus unknownNCT00081783Phase 2
• Alemtuzumab in Treating Patients With Waldenstrom's MacroglobulinemiaWithdrawnNCT00081068Phase 2
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaCompletedNCT00080886Phase 2
• Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell TransplantationCompletedNCT00080873Not applicable
• S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00080847Phase 2
• Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell LymphomaCompletedNCT00079755Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00079261Phase 2
• A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 YearsCompletedNCT00079105Phase 2
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
• Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or LymphomaCompletedNCT00078637Phase 1
• A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's LymphomaStatus unknownNCT00078598Phase 3
• Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHLTerminatedNCT00077961Phase 1/2
• BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaSuspendedNCT00077493Phase 1
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00077194Phase 2
• Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
• SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00076349Phase 2
• Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS LymphomaCompletedNCT00074191Phase 2
• Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS LymphomaCompletedNCT00074178Phase 2
• Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis FungoidesCompletedNCT00074087Phase 2
• Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073931Phase 2
• Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or LymphomaStatus unknownNCT00072488Not applicable

← Lymphoma overview